orforglipron

5 · 20 / page

Ask MedXY AI

Latest news

Tag

Diabetes & EndocrinologyACHIEVE-3Oral Semaglutide

Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial

By MedXY|Mar 6, 2026

The ACHIEVE-3 phase 3 trial demonstrates that orforglipron, a novel non-peptide oral GLP-1 receptor agonist, provides superior glycemic control compared to oral semaglutide in adults with type 2 diabetes, despite a higher frequency of gastr

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

Diabetes & EndocrinologyGLP-1 receptor agonistobesity

orforglipron

Latest news

Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena